IGF2BP2 and intrahepatic cholangiocarcinoma: The above results indicate that cPKM promotes ICC tumor proliferation, migration, and paclitaxel resistance by upregulating STMN1 expression and activating the AKT pathway through interactions with IGF2BP2 and miR‐199a‐5p.